Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 7/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 6/20 | 0.34 |
| ▸ | BIRC3 | Q13489 | 6/20 | 0.34 |
| ▸ | IL1B | P01584 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067395 | 0.89 | TNF (0.39) | TNFCNR1XIAPBIRC3IL1B | |
| SCHEMBL24067391 | 0.88 | TNF (0.40) | TNFCNR1XIAPBIRC3IL1B | |
| SCHEMBL24067457 | 0.88 | CNR1 (0.41) | TNFCNR1XIAPBIRC3IL1B | |
| SCHEMBL22450852 | 0.88 | CNR1 (0.41) | TNFCNR1XIAPBIRC3IL1B | |
| SCHEMBL24488619 | 0.87 | CNR1 (0.42) | TNFCNR1XIAPBIRC3IL1B | |
| SCHEMBL24067507 | 0.87 | TNF (0.40) | TNFCNR1XIAPBIRC3IL1B | |
| SCHEMBL22450625 | 0.85 | TNF (0.52) | TNFXIAPBIRC3BIRC2 | |
| SCHEMBL22450844 | 0.85 | TNF (0.52) | TNFXIAPBIRC3BIRC2 | |
| SCHEMBL24067397 | 0.83 | IL1B (0.32) | TNFXIAPBIRC3IL1BP2RX7 | |
| SCHEMBL22450721 | 0.81 | CNR1 (0.41) | TNFCNR1IL1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | TNF 1106/4885CNR1 4767/4885XIAP 2/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | TNF 1538/4885CNR1 4859/4885XIAP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.